Lumosa has signed a global exclusive license today (2025/4/21) with the University of North Carolina at Chapel Hill (UNC) for a patented “T-cell enhancement technology" to  strengthen its strategic position in regenerative medicine after  an earlier option agreement signed in late 2023. The licensed technology is designed to improve the efficacy of T-cell therapies, addressing critical challenges in expanding their use beyond hematological cancers to solid tumors and other indications. With full rights to develop, manufacture, and commercialize products incorporating this innovation—including next-generation CAR-T therapies. To accelerate the development, Lumosa will seek potential partners in the industry to collaborate with. The agreement includes upfront and milestone payments, royalties, and sublicensing income, with financial details to be disclosed in future reports. This move further consolidates the Company’s innovative strength in advancing high-impact therapies and unlocking new commercial opportunities in the evolving field of immunocellular treatment.